Carvedilol

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Carvedilol tablets should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.
• Take with food.
• Individualize dosages and monitor during up-titration.( 2 ) Left ventricular dysfunction following myocardial infarction:
• Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days.
• A lower starting dose or slower titration may be used.
• ( 2.2 ) Hypertension:
• Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.
• ( 2.3 )
• 2.2 Left Ventricular Dysfunction Following Myocardial Infarction DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION.
• Treatment with carvedilol tablets may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized.
• It is recommended that carvedilol tablets be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of 25 mg twice daily.
• A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention).
• Patients should be maintained on lower doses if higher doses are not tolerated.
• The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the myocardial infarction.
• 2.3 Hypertension DOSAGE MUST BE INDIVIDUALIZED.
• The recommended starting dose of carvedilol tablets is 6.25 mg twice daily.
• If this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide, the dose should be maintained for 7 to 14 days, and then increased to 12.5 mg twice daily if needed, based on trough blood pressure, again using standing systolic pressure one hour after dosing as a guide for tolerance.
• This dose should also be maintained for 7 to 14 days and can then be adjusted upward to 25 mg twice daily if tolerated and needed.
• The full antihypertensive effect of carvedilol tablets is seen within 7 to 14 days.
• Total daily dose should not exceed 50 mg.
• Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic component of carvedilol action.
• 2.4 Hepatic Impairment Carvedilol tablets should not be given to patients with severe hepatic impairment [see Contraindications (4) ].

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

• Effectiveness of carvedilol in patients younger than 18 years of age has not been established.
• In a double-blind trial, 161 children (mean age 6 years, range 2 months to 17 years; 45% less than 2 years old) with chronic heart failure [NYHA class II-IV, left ventricular ejection fraction <40% for children with a systemic left ventricle (LV), and moderate-severe ventricular dysfunction qualitatively by echo for those with a systemic ventricle that was not an LV] who were receiving standard background treatment were randomized to placebo or to 2 dose levels of carvedilol.
• These dose levels produced placebo-corrected heart rate reduction of 4-6 heart beats per minute, indicative of ß-blockade activity.
• Exposure appeared to be lower in pediatric subjects than adults.
• After 8 months of follow-up, there was no significant effect of treatment on clinical outcomes.
• Adverse reactions in this trial that occurred in greater than 10% of patients treated with carvedilol and at twice the rate of placebo-treated patients included chest pain (17% versus 6%), dizziness (13% versus 2%), and dyspnea (11% versus 0%).

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Of the 975 myocardial infarction patients randomized to carvedilol in the CAPRICORN trial, 48% (468) were 65 years of age or older, and 11% (111) were 75 years of age or older.
• Of the 2,065 hypertensive patients in US clinical trials of efficacy or safety who were treated with carvedilol, 21% (436) were 65 years of age or older.
• Of 3,722 patients receiving carvedilol tablets in hypertension clinical trials conducted worldwide, 24% were 65 years of age or older.
• With the exception of dizziness in hypertensive patients (incidence 8.8% in the elderly versus 6% in younger patients), no overall differences in the safety or effectiveness (see Figure 4 ) were observed between the older subjects and younger subjects in each of these populations.
• Similarly, other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

Quoted from the official label, section “Geriatric Use”.

Side effects

• Most common adverse events ( 6.1 ):
• Left ventricular dysfunction following myocardial infarction (≥10%):
• Dizziness, fatigue, hypotension, diarrhea, hyperglycemia, asthenia, bradycardia, weight increase Hypertension (≥5%):
• Dizziness To report SUSPECTED ADVERSE REACTIONS, contact Dr.
• Reddy’s Laboratories Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
• 6.1 Clinical Studies Experience Carvedilol tablets have been evaluated for safety in patients with left ventricular dysfunction following myocardial infarction and in hypertensive patients.
• The observed adverse event profile was consistent with the pharmacology of the drug and the health status of the patients in the clinical trials.
• Adverse events reported for each of these patient populations are provided below.
• Excluded are adverse events considered too general to be informative, and those not reasonably associated with the use of the drug because they were associated with the condition being treated or are very common in the treated population.
• Rates of adverse events were generally similar across demographic subsets (men and women, elderly and non-elderly, blacks and non-blacks).
• Left Ventricular Dysfunction Following Myocardial Infarction :
• Carvedilol tablets have been evaluated for safety in survivors of an acute myocardial infarction with left ventricular dysfunction in the CAPRICORN trial which involved 969 patients who received carvedilol tablets and 980 who received placebo.
• Approximately 75% of the patients received carvedilol tablets for at least 6 months and 53% received carvedilol tablets for at least 12 months.
• Patients were treated for an average of 12.9 months and 12.8 months with carvedilol tablets and placebo, respectively.
• The following adverse events were reported with a frequency of >1% but ≤3% and more frequently with carvedilol tablets:
• Flu syndrome, cerebrovascular accident, peripheral vascular disorder, hypotonia, depression, gastrointestinal pain, arthritis, and gout.
• The overall rates of discontinuations due to adverse events were similar in both groups of patients.
• In this database, the only cause of discontinuation >1%, and occurring more often on carvedilol was hypotension (1.5% on carvedilol, 0.2% on placebo).
• Hypertension :
• Carvedilol has been evaluated for safety in hypertension in more than 2,193 patients in US clinical trials and in 2,976 patients in international clinical trials.
• Approximately 36% of the total treated population received carvedilol tablets for at least 6 months.
• Most adverse events reported during therapy with carvedilol tablets were of mild to moderate severity.
• In US controlled clinical trials directly comparing carvedilol tablets in doses up to 50 mg (n = 1,142) to placebo (n = 462), 4.9% of patients receiving carvedilol tablets discontinued for adverse events versus 5.2% of placebo patients.
• Although there was no overall difference in discontinuation rates, discontinuations were more common in the carvedilol group for postural hypotension (1% versus 0).
• The overall incidence of adverse events in US placebo-controlled trials increased with increasing dose of carvedilol tablets.
• For individual adverse events this could only be distinguished for dizziness, which increased in frequency from 2% to 5% as total daily dose increased from 6.25 mg to 50 mg.
• Table 2 shows adverse events in US placebo-controlled clinical trials for hypertension that occurred with an incidence of ≥1% regardless of causality, and that were more frequent in drug-treated patients than placebo-treated patients.
• Table 2.
• Adverse Events (%) Occurring in US Placebo-Controlled Hypertension Trials (Incidence ≥1%, Regardless of Causality)* Shown are events with rate >1% rounded to nearest integer.
• Carvedilol Tablets Placebo (n = 1,142) (n = 462) Cardiovascular Bradycardia 2 — Postural hypotension 2 — Peripheral Edema 1 — Central Nervous System Dizziness 6 5 Insomnia 2 1 Gastrointestinal Diarrhea 2 1 Hematologic Thrombocytopenia 1 — Metabolic Hypertriglyceridemia 1 — Dyspnea and fatigue were also reported in these studies, but the rates were equal or greater in patients who received placebo.
• The following adverse events not described above were reported as possibly or probably related to carvedilol tablets in worldwide open or controlled trials with carvedilol in patients with hypertension.
• Incidence >0.1% to ≤ 1% Cardiovascular: Peripheral ischemia, tachycardia.
• Central and Peripheral Nervous System: Hypokinesia.
• Gastrointestinal:
• Bilirubinemia, increased hepatic enzymes (0.2% of hypertension patients were discontinued from therapy because of increases in hepatic enzymes) [see Adverse Reactions (6.2) ].
• Psychiatric:
• Nervousness, sleep disorder, aggravated depression, impaired concentration, abnormal thinking, paroniria, emotional lability.
• Respiratory System: Asthma [see Contraindications (4) ].
• Reproductive, male: Decreased libido.
• Skin and Appendages:
• Pruritus, rash erythematous, rash maculopapular, rash psoriaform, photosensitivity reaction.
• Special Senses: Tinnitus.
• Urinary System: Micturition frequency increased.
• Autonomic Nervous System: Dry mouth, sweating increased.
• Metabolic and Nutritional: Hypokalemia, hypertriglyceridemia.
• Hematologic: Anemia, leukopenia.
• The following events were reported in ≤0.1% of patients and are potentially important:
• Complete AV block, bundle branch block, myocardial ischemia, cerebrovascular disorder, convulsions, migraine, neuralgia, paresis, anaphylactoid reaction, alopecia, exfoliative dermatitis, amnesia, GI hemorrhage, bronchospasm, pulmonary edema, decreased hearing, respiratory alkalosis, increased BUN, decreased HDL, pancytopenia, and atypical lymphocytes.
• 6.2 Laboratory Abnormalities Reversible elevations in serum transaminases (ALT or AST) have been observed during treatment with carvedilol tablets.
• Rates of transaminase elevations (2- to 3-times the upper limit of normal) observed during controlled clinical trials have generally been similar between patients treated with carvedilol tablets and those treated with placebo.
• However, transaminase elevations, confirmed by rechallenge, have been observed with carvedilol tablets.
• In a long-term, placebo-controlled trial in severe heart failure, patients treated with carvedilol tablets had lower values for hepatic transaminases than patients treated with placebo, possibly because improvements in cardiac function induced by carvedilol led to less hepatic congestion and/or improved hepatic blood flow.
• Carvedilol tablets have not been associated with clinically significant changes in serum potassium, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine.
• No clinically relevant changes were noted in fasting serum glucose in hypertensive patients.
• 6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval use of carvedilol.
• Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
• Blood and Lymphatic System Disorders: Aplastic anemia.
• Immune System Disorders:
• Hypersensitivity (e.g., anaphylactic reactions, angioedema, urticaria).
• Renal and Urinary Disorders: Urinary incontinence.
• Respiratory, Thoracic and Mediastinal Disorders: Interstitial pneumonitis.
• Skin and Subcutaneous Tissue Disorders:
• Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• See FDA-Approved Patient Labeling (17.2)
• 17.1 Patient Advice Patients taking carvedilol tablets should be advised of the following:
• Patients should take carvedilol tablets with food.
• Patients should not interrupt or discontinue using carvedilol tablets without a physician's advice.
• Patients should consult their physician if they experience signs or symptoms of worsening heart failure such as weight gain or increasing shortness of breath.
• Patients may experience a drop in blood pressure when standing, resulting in dizziness and, rarely, fainting.
• Patients should sit or lie down when these symptoms of lowered blood pressure occur.
• If experiencing dizziness or fatigue, patients should avoid driving or hazardous tasks.
• Patients should consult a physician if they experience dizziness or faintness, in case the dosage should be adjusted.
• Diabetic patients should report any changes in blood sugar levels to their physician.
• Contact lens wearers may experience decreased lacrimation.
• 17.2 FDA-Approved Patient Labeling Patient labeling is provided as a tear-off leaflet at the end of this full prescribing information.
• Rx Only Manufactured by: Dr.
• Reddy’s Laboratories Limited Bachepalli – 502 325 INDIA Revised:
• 0811 FDA-Approved Patient Labeling PHARMACIST-DETACH FROM HERE ------------------------------------------------------------------------------------------------------------ PATIENT INFORMATION CARVEDILOL TABLETS USP Read the Patient Information that comes with carvedilol tablets before you start taking it and each time
• you get a refill.
• There may be new information.
• This information does not take the place of talking with your doctor about your medical condition or your treatment.
• If you have any questions about carvedilol tablets, ask your doctor or pharmacist.
• What is carvedilol? Carvedilol is a prescription medicine that belongs to a group of medicines called "beta-blockers".
• Carvedilol is used, often with other medicines, for the following conditions:
• To treat patients who had a heart attack that worsened how well the heart pumps To treat patients with high blood pressure (hypertension) Carvedilol tablets are not approved for use in
• children under 18 years of age.
• Who should not take carvedilol tablets?
• Do not take carvedilol tablets
• if you:
• Have severe heart failure and are hospitalized in the intensive care unit or require certain intravenous medications that help support circulation (inotropic medications) Are prone to asthma or other breathing problems Have a slow heartbeat or a heart that skips a beat (irregular heartbeat) Have liver problems Are allergic to any of the ingredients in carvedilol tablets.
• The active ingredient is carvedilol.
• See the end of this leaflet for a list of all the ingredients in carvedilol tablets.
• What should I tell my doctor before taking carvedilol tablets? Tell your doctor about all of your medical conditions, including
• if you:
• Have asthma or other lung problems (such as bronchitis or emphysema) Have problems with blood flow in your feet and legs (peripheral vascular disease) carvedilol tablets can make some of your symptoms worse.
• Have diabetes Have thyroid problems Have a condition called pheochromocytoma Have had severe allergic reactions Are pregnant or trying to become pregnant.
• It is not known if carvedilol tablets are safe for your unborn baby.
• You and your doctor should talk about the best way to control your high blood pressure during pregnancy.
• Are breastfeeding.
• It is not known if carvedilol tablets passes into your breast milk.
• You should not breastfeed while using carvedilol tablets.
• Are scheduled for surgery and will be given anesthetic agents Are scheduled for cataract surgery and have taken or are currently taking carvedilol.
• Are taking prescription or non-prescription medicines, vitamins, and herbal supplements.
• Carvedilol tablets and certain other medicines can affect each other and cause serious side effects.
• Carvedilol tablets may affect the way other medicines work.
• Also, other medicines may affect how well Carvedilol tablet works Keep a list of all the medicines
• you take.
• Show this list to your doctor and pharmacist before you start a new medicine.
• How should I take carvedilol tablets? It is important for you to take your medicine every day as directed by your doctor.
• If you stop taking carvedilol tablets suddenly, you could have chest pain and/or a heart attack.
• If your doctor decides that you should stop taking carvedilol tablets, your doctor may slowly lower your dose over a period of time before stopping it completely.
• Take carvedilol tablets exactly as prescribed.
• Your doctor will tell you how many tablets to take and how often.
• In order to minimize possible side effects, your doctor might begin with a low dose and then slowly increase the dose.
• Do not stop taking carvedilol tablets and do not change the amount of carvedilol tablets
• you take without talking to your doctor.
• Tell your doctor
• if you gain weight or have trouble breathing while taking carvedilol tablets.
• Take carvedilol tablets with food.
• If you miss a dose of carvedilol tablets, take your dose as soon as you remember, unless it is time to take your next dose.
• Take your next dose at the usual time.
• Do not take 2 doses at the same time.
• If you take too much carvedilol tablets, call your doctor or poison control center right away.
• What should I
• avoid while taking carvedilol tablets? Carvedilol tablets can cause you to feel dizzy, tired, or faint.
• Do not drive a car, use machinery, or do anything that needs you to be alert
• if you have these symptoms.
• What are possible side effects of carvedilol tablets? Low blood pressure (which may cause dizziness or fainting when you stand up).
• If these happen, sit or lie down right away and tell your doctor.
• Tiredness.
• If you feel tired or dizzy you should not drive, use machinery, or do anything that needs you to be alert.
• Slow heart beat Changes in your blood sugar.
• If you have diabetes, tell your doctor
• if you have any changes in your blood sugar levels.
• Carvedilol tablets may hide some of the symptoms of low blood sugar, especially a fast heartbeat.
• Carvedilol tablets may mask the symptoms of hyperthyroidism (overactive thyroid).
• Worsening of severe allergic reactions.
• Rare but serious allergic reactions (including hives or swelling of the face, lips, tongue and/or throat that may cause difficulty breathing or swallowing) have happened in patients who were on carvedilol tablets.
• These reactions can be life-threating.
• Other side effects of carvedilol tablets include shortness of breath, weight gain, diarrhea, and fewer tears or dry eyes that become bothersome
• if you wear contact lenses.
• Call your doctor if you have any side effects that bother you or don't go away.
• How should I store carvedilol tablets? Store carvedilol tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].
• Keep the tablets dry.
• Safely, throw away carvedilol tablets that is out of date or no longer needed.
• Keep carvedilol tablets and all medicines out of the reach of children.
• General Information About Carvedilol Tablets Medicines are sometimes prescribed for conditions other than those described in patient information leaflets.
• Do not use carvedilol tablets for a condition for which it was not prescribed.
• Do not give carvedilol tablets to other people, even if they have the same symptoms
• you have.
• It may harm them.
• This leaflet summarizes the most important information about carvedilol tablets.
• If you would like more formation, talk with your doctor.
• You can ask your doctor or pharmacist for information about carvedilol tablets that is written for healthcare professionals.
• You can also find out more about carvedilol tablets by calling 1-888-375-3784.
• This call is free.
• What are the ingredients in carvedilol? Active Ingredient:
• Carvedilol USP Inactive Ingredients:
• colloidal silicon dioxide, crospovidone, hypromellose 2910-5cP, lactose monohydrate, magnesium stearate, polyethylene glycol 400, polysorbate 80, povidone, synthetic yellow iron oxide and titanium dioxide.
• Carvedilol tablets USP come in the following strengths:
• 3.125 mg, 6.25 mg, 12.5 mg, 25 mg What is high blood pressure (hypertension)? Blood pressure is the force of blood in your blood vessels when your heart beats and when your heart rests.
• You have high blood pressure when the force is too much.
• High blood pressure makes the heart work harder to pump blood through the body and causes damage to blood vessels.
• Carvedilol tablets can help your blood vessels relax so your blood pressure is lower.
• Medicines that lower blood pressure may lower your chance of having a stroke or heart attack.
• To reorder additional Patient Information Sheets contact Dr.
• Reddy’s Customer Service at 1-866-733-3952.
• Rx Only Manufactured by: Dr.
• Reddy's Laboratories Limited Bachepalli – 502 325 INDIA Revised: 0811

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS The round, film coated tablets are available in the following strengths:
• 3.125 mg– yellow colored, debossed with R and 252, 6.25 mg– white colored, debossed with R and 253, 12.5 mg– white colored, debossed with R and 254, and 25 mg– white colored, debossed with R and 255.
• Tablets: 3.125, 6.25, 12.5, 25 mg ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• Carvedilol tablets USP 3.125 mg are yellow, round, film coated tablets debossed with 'R' on one side and '252' on other side and are supplied in bottles of 30, 100, 500, 1000 and unit dosage packages of 100 (10 × 10).
• Bottles of 30 NDC 55111-252-30 Bottles of 100 NDC 55111-252-01 Bottles of 500 NDC 55111-252-05 Bottles of 1000 NDC 55111-252-10 Unit dose packages of 100 (10 ×10) NDC 55111-252-78 Carvedilol tablets USP 6.25 mg are white, round, film coated tablets debossed with 'R' on one side and '253' on other side and are supplied in bottles of 30, 100, 500, 1000 and unit-dose packages of 100 (10 × 10).
• Bottles of 30 NDC 55111-253-30 Bottles of 100 NDC 55111-253-01 Bottles of 500 NDC 55111-253-05 Bottles of 1000 NDC 55111-253-10 Unit dose packages of 100 (10 ×10) NDC 55111-253-78 Carvedilol tablets USP 12.5 mg are white, round, film coated tablets debossed with 'R' on one side and '254' on other side and are supplied in bottles of 30, 100, 500, 1000 and unit-dose packages of 100 (10 × 10).
• Bottles of 30 NDC 55111-254-30 Bottles of 100 NDC 55111-254-01 Bottles of 500 NDC 55111-254-05 Bottles of 1000 NDC 55111-254-10 Unit dose packages of 100 (10 ×10) NDC 55111-254-78 Carvedilol tablets USP 25 mg are white, round, film coated tablets debossed with 'R' on one side and '255' on other side and are supplied in bottles of 30, 100, 500, 1000 and unit-dose packages of 100 (10 × 10).
• Bottles of 30 NDC 55111-255-30 Bottles of 100 NDC 55111-255-01 Bottles of 500 NDC 55111-255-05 Bottles of 1000 NDC 55111-255-10 Unit dose packages of 100 (10 ×10) NDC 55111-255-78
• Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].
• Protect from moisture.
• Dispense in a tight, light-resistant container.

Quoted from the official label, section “How Supplied”.

How to store it

Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container.

Quoted from the official label, section “Storage and Handling”.

What is in it

• Carvedilol USP is a nonselective β-adrenergic blocking agent with α 1 -blocking activity.
• It is (±)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol.
• Carvedilol USP is a racemic mixture with the following structure:
• Carvedilol tablets USP are film-coated tablets containing 3.125 mg, 6.25 mg, 12.5 mg or 25 mg of carvedilol.
• Carvedilol tablets USP 3.125 mg are yellow in color and 6.25 mg, 12.5 mg and 25 mg tablets are white in color.
• Inactive ingredients consist of colloidal silicon dioxide, crospovidone, hypromellose 2910-5cP, lactose monohydrate, magnesium stearate, polyethylene glycol 400, polysorbate 80, povidone, synthetic yellow iron oxide and titanium dioxide.
• Carvedilol USP is a white to off-white powder with a molecular weight of 406.5 and a molecular formula of C 24 H 26 N 2 O 4 .
• It is freely soluble in dimethylsulfoxide; soluble in methylene chloride and methanol; sparingly soluble in 95% ethanol and isopropanol; slightly soluble in ethyl ether; and practically insoluble in water, gastric fluid (simulated, TS, pH 1.1) and intestinal fluid (simulated, TS without pancreatin, pH 7.5).
• Carvedilol Tablets meet USP Dissolution Test 2. structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

116 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

See every product with Carvedilol